20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immix Biopharma Inc (IMMX) operates in the BIOTECHNOLOGY industry and is headquartered in Los Angeles, United States with about 21 employees. Its market capitalization is roughly $894 million. In the fiscal year ended 2025-12-31, IMMX reported $0M in revenue and ($29M) in net income.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | ($90M) | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | ($90M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | 100.0% | — | — | — |
| Operating Income (EBIT) | ($42M) | ($30M) | ($23M) | ($16M) | ($8M) | ($1M) | $0M | ($1M) |
| Operating Margin % | — | — | — | — | 9.2% | — | — | — |
| Net Income | ($40M) | ($29M) | ($22M) | ($15M) | ($8M) | ($24M) | ($1M) | ($1M) |
| Net Margin % | — | — | — | — | 9.2% | — | — | — |
| EBITDA | ($40M) | ($30M) | ($22M) | ($16M) | ($8M) | ($24M) | $0M | ($1M) |
| Earnings Per Share (EPS) | $-0.88 | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-6.64 | $-0.15 | $-0.29 |
| Shares Outstanding (M) | 64M | 33M | 28M | 17M | 14M | 4M | 8M | 3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($11M) | ($8M) | ($7M) | ($5M) | ($5M) | ($7M) |
| Operating Margin % | — | — | — | — | — | — | -5179.3% | — |
| Net Income | ($12M) | ($10M) | ($11M) | ($8M) | ($7M) | ($5M) | ($5M) | ($7M) |
| Net Margin % | — | — | — | — | — | — | -4997.5% | — |
| EBITDA | ($12M) | ($11M) | ($11M) | ($7M) | ($7M) | ($4M) | ($5M) | ($7M) |
| Earnings Per Share (EPS) | $-0.18 | $-0.18 | $-0.28 | $-0.24 | $-0.22 | $-0.15 | $-0.17 | $-0.24 |
| Shares Outstanding (M) | 64M | 55M | 38M | 32M | 30M | 30M | 28M | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($38M) | ($24M) | ($15M) | ($11M) | ($7M) | ($2M) | $0M | ($1M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($39M) | ($25M) | ($16M) | ($11M) | ($7M) | ($2M) | $0M | ($1M) |
| FCF Margin % | — | — | — | — | 8.3% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($12M) | ($10M) | ($11M) | ($6M) | ($5M) | ($2M) | ($1M) | ($4M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | ($12M) | ($10M) | ($11M) | ($6M) | ($5M) | ($2M) | ($2M) | ($4M) |
| FCF Margin % | — | — | — | — | — | — | -2059.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $239M | $105M | $23M | $20M | $15M | $18M | $1M | $1M |
| Cash & Cash Equivalents | $225M | $94M | $18M | $18M | $13M | $18M | $0M | $1M |
| Total Liabilities | $10M | $11M | $10M | $4M | $2M | $0M | $5M | $5M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $4M | $4M |
| Total Shareholders' Equity | $229M | $94M | $13M | $16M | $13M | $18M | ($5M) | ($4M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMMX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms